Prof Frank Griesinger, medical oncologist at Pius Hospital, Oldenburg, Germany presents real-world data and outcomes in the US and Germany after first-line treatment with osimertinib  in patients with EGFRm advanced NSCLC.

With the educational support of:

You may also be interested in:

FLAURA2 post-progression outcomes

The remaining challenges with neo-adjuvant immunotherapy in early-stage NSCLC

PULSE, a non-inferiority study of maintenance Pembro at Usual or Low doSE

Tags:

poster